CA2881317A1 - A method for the induction of an immune response - Google Patents

A method for the induction of an immune response Download PDF

Info

Publication number
CA2881317A1
CA2881317A1 CA2881317A CA2881317A CA2881317A1 CA 2881317 A1 CA2881317 A1 CA 2881317A1 CA 2881317 A CA2881317 A CA 2881317A CA 2881317 A CA2881317 A CA 2881317A CA 2881317 A1 CA2881317 A1 CA 2881317A1
Authority
CA
Canada
Prior art keywords
antigen
vertebrate
antibodies
complexes
mixtures
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2881317A
Other languages
English (en)
French (fr)
Inventor
Geoffrey W . Hoffmann
Sybille Muller
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Network Immunology Inc
Original Assignee
Network Immunology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Network Immunology Inc filed Critical Network Immunology Inc
Publication of CA2881317A1 publication Critical patent/CA2881317A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39566—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against immunoglobulins, e.g. anti-idiotypic antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/112—Retroviridae (F), e.g. leukemia viruses
    • C07K16/114—Lentivirus (G), e.g. human immunodeficiency virus [HIV], feline immunodeficiency virus [FIV] or simian immunodeficiency virus [SIV]
    • C07K16/1145—Env proteins, e.g. gp41, gp110/120, gp160, V3, principal neutralising domain [PND] or CD4-binding site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C07K16/4216—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-viral Ig
    • C07K16/4225—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-viral Ig against anti-HIV Ig
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • AIDS & HIV (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CA2881317A 2012-08-08 2013-08-08 A method for the induction of an immune response Abandoned CA2881317A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201261681040P 2012-08-08 2012-08-08
US61/681,040 2012-08-08
US201261727539P 2012-11-16 2012-11-16
US61/727,539 2012-11-16
US201361801153P 2013-03-15 2013-03-15
US61/801,153 2013-03-15
PCT/CA2013/000710 WO2014022924A1 (en) 2012-08-08 2013-08-08 A method for the induction of an immune response

Publications (1)

Publication Number Publication Date
CA2881317A1 true CA2881317A1 (en) 2014-02-13

Family

ID=50067331

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2881317A Abandoned CA2881317A1 (en) 2012-08-08 2013-08-08 A method for the induction of an immune response

Country Status (5)

Country Link
US (1) US20150216973A1 (enExample)
EP (1) EP2882455A4 (enExample)
CA (1) CA2881317A1 (enExample)
IN (1) IN2015DN01483A (enExample)
WO (1) WO2014022924A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107847591B (zh) * 2015-04-17 2023-07-28 Igm生物科学股份有限公司 多价人免疫缺陷病毒抗原结合分子及其应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE255902T1 (de) * 1992-03-09 2003-12-15 San Diego Regional Cancer Ct Ein anti-idiotypischer antikörper und seine verwendung in der diagnose und therapie von hiv- verwandten krankheiten
US20040180050A1 (en) * 1994-05-31 2004-09-16 Hoffman Geoffrey W. Inverse skewing of the lymphocyte repertoire for therapy and prevention of disease
US6057421A (en) * 1994-11-30 2000-05-02 Immpheron, Inc. Variable heavy and light chain regions of murine monoclonal antibody 1F7
WO2003059953A2 (en) * 2002-01-17 2003-07-24 Polymun Scientific Immunbiologische Forschung Gmbh Anti-idiotypic antibody inducing hiv-1 neutralizing antibodies
US20100150960A1 (en) * 2006-09-22 2010-06-17 The United States Of America, As Represented By The Secretary,Department Of Health And Human Servi Compositions and methods for chitosan enhanced immune response

Also Published As

Publication number Publication date
IN2015DN01483A (enExample) 2015-07-03
WO2014022924A1 (en) 2014-02-13
EP2882455A1 (en) 2015-06-17
EP2882455A4 (en) 2016-03-23
US20150216973A1 (en) 2015-08-06

Similar Documents

Publication Publication Date Title
US10836829B2 (en) Anti-WT1/HLA-specific antibodies
ES2822135T3 (es) Anticuerpos anti-VIH ampliamente neutralizantes
US10654915B2 (en) Antibodies useful in passive influenza immunization
JP2012102122A5 (enExample)
RU2013148537A (ru) Стабильные составы антител против рецептора программируемой смерти pd-1 человека и относящиеся к ним способы лечения
JP2014533279A5 (enExample)
FI3569620T3 (fi) Ihmisen cgrp-reseptoria sitovat vasta-aineet
JP2020513855A5 (enExample)
AU2015332634B2 (en) Composition with reduced immunogenicity
JP2019503387A5 (enExample)
JP2012530487A5 (enExample)
RU2013102073A (ru) Антитела, подходящие для пассивной иммунизации против гриппа
JP2016509585A5 (enExample)
Gopi et al. Introducing metallocene into a triazole peptide conjugate reduces its off‐rate and enhances its affinity and antiviral potency for HIV‐1 gp120
US20150216973A1 (en) Method for the induction of an immune response
Shcheblyakov et al. Development and characterization of two GP-specific monoclonal antibodies, which synergistically protect non-human primates against Ebola lethal infection
JP2015529656A5 (enExample)
Li et al. Identification of critical antibody-binding sites in the HIV-1 gp41 six-helix bundle core as potential targets for HIV-1 fusion inhibitors
IL305600A (en) Multispecific binding regions containing novel PD-1 binding regions
Thomas et al. Progress in the development of structure-based vaccines
US20230210868A1 (en) Methods of Treatment Using ICAM-Modulating Agents
Wang et al. Neutralization of SARS-CoV-2 infection by antibodies targeting diverse epitopes
TW202302630A (zh) 新穎多特異性抗體
CA3154556A1 (en) Compositions and methods related to human neutralizing antibodies to hepatitis b
JP2008531719A5 (enExample)

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20170808